The 2 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 1.25, with a high estimate of 1.40 and a low estimate of 1.11. The median estimate represents a -5.28% decrease from the last price of 1.33.
The current consensus among 4 polled investment analysts is to Hold stock in Zynerba Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.20
Reporting Date Nov 13
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.